Wockhardt has received approval for raising of funds through issuance of Non-Convertible Debentures (NCDs)/ Bonds (secured/ unsecured) on Private Placement basis up to an aggregate amount not exceeding Rs 1,800 crore.

The Board of Directors of the company at its meeting held on November 10, 2018 has approved the same.

Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.